SCLP

SCANCELL HOLDINGS PLC ORD 0.1P

TitleTime
Director salaries and award of share optionsFri 01/05/20 | 07:00
Second Price Monitoring ExtnWed 29/04/20 | 14:06
Price Monitoring ExtensionWed 29/04/20 | 14:00
Director DealingTue 28/04/20 | 10:06
Director DealingMon 27/04/20 | 16:39
Second Price Monitoring ExtnFri 24/04/20 | 14:05
Price Monitoring ExtensionFri 24/04/20 | 14:00
Scancell: Development of vaccine against COVID-19Fri 24/04/20 | 07:00
Second Price Monitoring ExtnMon 16/03/20 | 16:42
Price Monitoring ExtensionMon 16/03/20 | 16:38
SCIB1 IND Application ApprovedMon 03/02/20 | 07:00
Interim ResultsFri 31/01/20 | 07:00
Third agreement signed for antibody platformMon 20/01/20 | 07:00
Director's DealingsTue 17/12/19 | 12:44
Second agreement signed for AvidiMab platformMon 16/12/19 | 07:00
New European Moditope patent allowed for grantWed 20/11/19 | 07:00
Directorate ChangeWed 23/10/19 | 07:00
Posters at Cancer Immunotherapy ConferenceThu 26/09/19 | 07:00
Result of AGMThu 12/09/19 | 15:56
First Collaboration Agreement for AvidiMabWed 04/09/19 | 07:00
Notice of AGMTue 20/08/19 | 14:23
Final Results for the year ended 30 April 2019Tue 20/08/19 | 07:00
Update on the SCIB1 Phase 2 clinical trialMon 19/08/19 | 07:00
Notice of Final ResultsWed 07/08/19 | 07:00
Holding(s) in CompanyTue 18/06/19 | 09:16
Board AppointmentTue 18/06/19 | 07:00
Holding(s) in CompanyMon 17/06/19 | 10:45
Second Price Monitoring ExtnFri 14/06/19 | 16:41
Price Monitoring ExtensionFri 14/06/19 | 16:35
Share Subscription and Issue of Equity to VulpesThu 13/06/19 | 07:00
Second Price Monitoring ExtnWed 29/05/19 | 11:05
Price Monitoring ExtensionWed 29/05/19 | 11:00
UK approval to start SCIB1 Phase 2 trialThu 25/04/19 | 07:00
Scancell strengthens IP portfolioWed 20/03/19 | 07:00
Holding(s) in CompanyTue 05/03/19 | 18:27
Second Price Monitoring ExtnMon 04/03/19 | 16:40
Price Monitoring ExtensionMon 04/03/19 | 16:35
Change of AuditorThu 21/02/19 | 07:00
Interim ResultsThu 31/01/19 | 07:00
Results of AGMTue 30/10/18 | 17:18
Identification of 2nd Moditope Cancer VaccineTue 30/10/18 | 07:00
Second Price Monitoring ExtnWed 24/10/18 | 09:05
Price Monitoring ExtensionWed 24/10/18 | 09:00
Update on SCIB1 Phase 2 Clinical StudyWed 24/10/18 | 07:00
Notice of AGMFri 05/10/18 | 07:00
Final Results for the year ended 30 April 2018Tue 25/09/18 | 07:00
Notice of Final ResultsTue 18/09/18 | 07:00
Board ChangeFri 10/08/18 | 07:00
AgreementThu 09/08/18 | 07:00
Director/PDMR ShareholdingWed 25/07/18 | 14:45
Issue of EquityTue 24/07/18 | 07:00
Scancell exercises TriGrid commercial optionWed 18/07/18 | 07:00
Holding(s) in CompanyFri 11/05/18 | 13:11
Holding(s) in CompanyWed 09/05/18 | 10:12
Result of the Open Offer and PDMR ShareholdingsTue 08/05/18 | 07:00
Holding(s) in CompanyMon 23/04/18 | 12:43
Holding(s) in CompanyFri 20/04/18 | 16:32
Result of Placing and Subscription and PDMRWed 18/04/18 | 14:29
Second Price Monitoring ExtnWed 18/04/18 | 11:05
Price Monitoring ExtensionWed 18/04/18 | 11:00
Proposed Placing, Subscription and Open OfferWed 18/04/18 | 07:00
Collaboration agreement with ISA PharmaceuticalsThu 15/02/18 | 07:00
Publication highlights potential of SCIB1 therapyMon 12/02/18 | 07:00
European patent application allowed for grantFri 09/02/18 | 07:00
Director/PDMR ShareholdingThu 01/02/18 | 07:00
Half-year ReportTue 30/01/18 | 07:00
Scancell to collaborate with BioNTechTue 09/01/18 | 07:00
Scancell and CRUK to advance cancer immunotherapyThu 14/12/17 | 07:00
Result of AGMWed 11/10/17 | 09:44
Directorate ChangeTue 10/10/17 | 07:00
Notice of AGMThu 14/09/17 | 07:00
Final ResultsWed 13/09/17 | 07:00
Continued Progress on SCIB1Tue 11/07/17 | 07:00